3/13
06:18 am
maze
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
Medium
Report
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
3/13
06:18 am
maze
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
Medium
Report
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
3/10
08:03 am
maze
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
High
Report
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
3/10
08:03 am
maze
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
High
Report
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
3/10
05:49 am
maze
Rating for MAZE
High
Report
Rating for MAZE
3/10
05:49 am
maze
Rating for MAZE
High
Report
Rating for MAZE
3/10
04:41 am
maze
Maze Therapeutics initiated with an Outperform at Mizuho
High
Report
Maze Therapeutics initiated with an Outperform at Mizuho
3/10
04:41 am
maze
Maze Therapeutics initiated with an Outperform at Mizuho
High
Report
Maze Therapeutics initiated with an Outperform at Mizuho
3/9
08:03 am
maze
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Low
Report
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
3/9
06:24 am
maze
Rating for MAZE
Low
Report
Rating for MAZE
3/4
08:22 am
maze
Rating for MAZE
Medium
Report
Rating for MAZE
3/4
08:22 am
maze
Rating for MAZE
Medium
Report
Rating for MAZE
1/28
10:12 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/16
12:23 pm
maze
Rating for MAZE
Low
Report
Rating for MAZE
12/19
09:09 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/19
09:09 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at Guggenheim.